154 related articles for article (PubMed ID: 23067211)
1. Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy.
Huang W; Ding X; Li B; Fan M; Zhou T; Sun H; Yi Y; Zhang J
Neoplasma; 2013; 60(1):11-8. PubMed ID: 23067211
[TBL] [Abstract][Full Text] [Related]
2. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Li CH; Liu MY; Liu W; Li DD; Cai L
Asian Pac J Cancer Prev; 2014; 15(2):731-6. PubMed ID: 24568487
[TBL] [Abstract][Full Text] [Related]
3. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
Lan WG; Hao YZ; Xu DH; Wang P; Zhou YL; Ma LB
Clin Transl Oncol; 2016 Apr; 18(4):375-80. PubMed ID: 26329292
[TBL] [Abstract][Full Text] [Related]
4. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
Dang J; Li G; Zang S; Zhang S; Yao L
Radiat Oncol; 2014 Jul; 9():172. PubMed ID: 25074618
[TBL] [Abstract][Full Text] [Related]
5. Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer.
Zhao Q; Wang Z; Huang W; Wang Q; Yu S; Zhou T; Han D; Wu Z; Gong H; Sun H; Zhang J; Wei Y; Li H; Zhang Z; Lin H; Li B
Oncotarget; 2016 Feb; 7(7):8422-31. PubMed ID: 26761213
[TBL] [Abstract][Full Text] [Related]
6. Effect analysis of chemoradiotherapy after operation in patients with stage III A non-small cell lung cancer.
Chen S; Cheng YL; Li ST; Ni YJ; Gu B
Asian Pac J Trop Med; 2012 Oct; 5(10):823-7. PubMed ID: 23043924
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
[TBL] [Abstract][Full Text] [Related]
9. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Scagliotti G; Brodowicz T; Shepherd FA; Zielinski C; Vansteenkiste J; Manegold C; Simms L; Fossella F; Sugarman K; Belani CP
J Thorac Oncol; 2011 Jan; 6(1):64-70. PubMed ID: 21119545
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
Treat J; Scagliotti GV; Peng G; Monberg MJ; Obasaju CK; Socinski MA
Lung Cancer; 2012 May; 76(2):222-7. PubMed ID: 22115704
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
Najjar F; Alammar M; Bachour M; Almalla N; Altahan M; Alali A; Al-Massarani G
J Cancer Res Clin Oncol; 2015 Jan; 141(1):119-25. PubMed ID: 25037116
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer.
Choy H; Schwartzberg LS; Dakhil SR; Garon EB; Gerber DE; Choksi JK; Govindan R; Peng G; Koustenis A; Treat J; Obasaju C
J Thorac Oncol; 2013 Oct; 8(10):1308-16. PubMed ID: 23981966
[TBL] [Abstract][Full Text] [Related]
14. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.
Descourt R; Vergnenegre A; Barlesi F; Lena H; Fournel P; Falchero L; Berard H; Hureaux J; Le Caer H; Chavaillon JM; Geriniere L; Monnet I; Chouabe S; Robinet G;
J Thorac Oncol; 2011 Feb; 6(2):351-7. PubMed ID: 21164367
[TBL] [Abstract][Full Text] [Related]
15. A landmark point analysis with cytotoxic agents for advanced NSCLC.
Yamamoto N; Nambu Y; Fujimoto T; Koshiji M
J Thorac Oncol; 2009 Jun; 4(6):697-701. PubMed ID: 19318995
[TBL] [Abstract][Full Text] [Related]
16. HIF-1α Levels in patients receiving chemoradiotherapy for locally advanced non-small cell lung carcinoma.
Afsar CU; Uysal P
Rev Assoc Med Bras (1992); 2019; 65(10):1295-1299. PubMed ID: 31721962
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
Syrigos KN; Vansteenkiste J; Parikh P; von Pawel J; Manegold C; Martins RG; Simms L; Sugarman KP; Visseren-Grul C; Scagliotti GV
Ann Oncol; 2010 Mar; 21(3):556-561. PubMed ID: 19828561
[TBL] [Abstract][Full Text] [Related]
18. Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Maráz A; Furák J; Varga Z; Fodor E; Együd Z; Borzási E; Kahán Z; Pálföldi R; Tiszlavicz L; Hideghéty K
Anticancer Res; 2013 Apr; 33(4):1737-41. PubMed ID: 23564825
[TBL] [Abstract][Full Text] [Related]
19. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
Scagliotti G; Hanna N; Fossella F; Sugarman K; Blatter J; Peterson P; Simms L; Shepherd FA
Oncologist; 2009 Mar; 14(3):253-63. PubMed ID: 19221167
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.
Dingemans AM; Bootsma G; van Baardwijk A; Reymen B; Wanders R; Brans B; Das M; Hochstenbag M; van Belle A; Houben R; Lambin P; de Ruysscher D
J Thorac Oncol; 2014 May; 9(5):710-6. PubMed ID: 24722157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
